Skip to main content
. 2021 Jun 9;11:12114. doi: 10.1038/s41598-021-91630-4

Figure 2.

Figure 2

Cumulative probability of late-onset antibody-mediated rejection according to tacrolimus IPV (A) high immunological risk group, (B) low immunological risk group.